Aromatase inhibitors: a safety comparison

Bibliography

• PARKIN DM, BRAY F, FERLAY J, PISANI P: Global cancer statistics, 2002. CA Cancer J. Clin. (2005) 55:74-108.
   PubMed Web of Science ®Google Scholar
• EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 365:1687-1717.
   PubMed Web of Science ®Google Scholar
• FISHER B, COSTANTINO JP, REDMOND CK et al.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. (1994) 86:527-537.
   PubMed Web of Science ®Google Scholar
• LEWIS JS, JORDAN VC: Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. (2005) 591:247-263.
   PubMed Web of Science ®Google Scholar
• BUZDAR A, ROBERTSON JFR, EIERMANN W, NABHOLTZ JM: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer (2002) 95:2006-2016.
   PubMed Web of Science ®Google Scholar
• GEISLER J, HAYNES B, ANKER G, DOWSETT M, LØNNING PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. (2002) 20:751-757.
   PubMed Web of Science ®Google Scholar
• WINER EP, HUDIS C, BURSTEIN HJ et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. (2005) 23:619-629.
   PubMed Web of Science ®Google Scholar
• ATAC TRIALISTS’ GROUP: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet (2005) 365:60-62.
   PubMed Web of Science ®Google Scholar
• BOCCARDO F, RUBAGOTTI A, PUNTONI M et al.: Switching to anastrozole (ANA) versus continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. J. Clin. Oncol. (Meeting Abstracts) (2005) 23:10s.
   Google Scholar
• COOMBES RC, HALL E, GIBSON LJ et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. (2004) 350:1081-1092.
   PubMed Web of Science ®Google Scholar
• COOMBES RC, PARIDAENS R, JASSEM J et al.: First mature analysis of the Intergroup Exemestane Study. J. Clin. Oncol. (Meeting Abstracts) (2006) 24:LBA527.
   PubMedGoogle Scholar
• GOSS PE, INGLE JN, MARTINO S et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. (2005) 97:1262-1271.
   PubMed Web of Science ®Google Scholar
• JAKESZ R, JONAT W, GNANT M et al.: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet (2005) 366:455-462.
   PubMed Web of Science ®Google Scholar
• KAUFMANN M, JONAT W, HILFRICH J et al.: Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. Am. Soc. Clin. Oncol. (Meeting Abstracts) (2006) 24:547.
   PubMedGoogle Scholar
• THE ATAC TRIALISTS’ GROUP: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. (2006) 7:633-643.
   PubMed Web of Science ®Google Scholar
• THE BREAST INTERNATIONAL GROUP (BIG) 1-98 COLLABORATIVE GROUP: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. (2005) 353:2747-2757.
   PubMed Web of Science ®Google Scholar
• THE ATAC TRIALISTS’ GROUP: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (2002) 359:2131-2139.
   PubMed Web of Science ®Google Scholar
• MEDICINES AND HEALTHCARE PRODUCTS REGISTORY AGENCY: Public assessment report femara 2.5mg tablet. (2005):PL00101/0493.
   Google Scholar
• COATES AS, MOURIDSEN H, MAURIAC L: Letrozole or tamoxifen in early breast cancer [letter]. N. Engl. J. Med. (2006) 354:1529-1529.
   Google Scholar
• HOWELL A: ATAC trial update [letter]. Lancet (2005) 365:1225-1226.
   Google Scholar
• WOJTACKI J, LESNIEWSKI-KMAK K, PIOTROWSKA M et al.: Effect of anastrozole on serum levels of apolipoprotein A-I and B in patients with early breast cancer: additional data on lack of atherogenic properties. Breast Cancer Res. Treat. (2004) 88:S238.
   Google Scholar
• WOJTACKI J, LESNIEWSKI-KMAK K, PAWLAK W, NOWICKA E: Anastrozole therapy and lipid profile: an update. Eur. J. Cancer Suppl. (2004) 2:142.
   Web of Science ®Google Scholar
• DEWAR J, NABHOLTZ J-MA, BONNETERRE J et al.: The effect of anastrozole (ArimidexTM) on serum lipids – data from a randomized comparison of anastrozole (AN) versus tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res. Treat. (2000) 64(Suppl.):S51.
   Google Scholar
• KATAJA V, HIETANEN P, JOENSUU H et al.: The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer – a randomised study. Breast Cancer Res. Treat. (2002) 76(Suppl. 1):S156.
   Google Scholar
• BOCCARDO F, RUBAGOTTI A, PUNTONI M et al.: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J. Clin. Oncol. (2005) 23:5138-5147.
   PubMed Web of Science ®Google Scholar
• ELISAF MS, BAIRAKTARI ET, NICOLAIDES C et al.: Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur. J. Cancer (2001) 37:1510-1513.
   PubMed Web of Science ®Google Scholar
• WASAN KM, GOSS PE, PRITCHARD PH et al.: The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann. Oncol. (2005) 16:707-715.
   PubMed Web of Science ®Google Scholar
• ATALAY G, DIRIX L, BIGANZOLI L et al.: The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ‘Randomized Phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’. Ann. Oncol. (2004) 15:211-217.
   PubMed Web of Science ®Google Scholar
• GONNELLI S, MONTAGNANI A, CADIRINI A et al.: Lipid profile and body composition in postmenopausal women with breast cancer treated with exemestane or tamoxifen. Nutr. Metab. Cardiovasc. Dis. (2004) 14:305.
   Google Scholar
• MARKOPOULOS C, POLYCHRONIS A, ZOBOLAS V et al.: The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res. Treat. (2005) 93:61-66.
   PubMed Web of Science ®Google Scholar
• MCCLOSKEY E, EASTELL R, LAKNER G, MIYAMOTO A, CLACK G: Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res. Treat. (2005) 94:S101.
   Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (1998) 90:1371-1388.
   PubMed Web of Science ®Google Scholar
• WRITING GROUP FOR THE WOMEN’S HEALTH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA (2002) 288:321-333.
   PubMed Web of Science ®Google Scholar
• THÜRLIMANN B, ROBERTSON JFR, BONNETERRE J: Efficacy of tamoxifen following arimidex (anastrozole) as first-line treatment for advanced breast cancer (ABC) in postmenopausal women (PM). Breast Cancer Res. Treat. (2000) 64:51.
   Google Scholar
• BUZDAR A, CHLEBOWSKI R, CUZICK J et al.: Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr. Med. Res. Opin. (2006) 22:1575-1585.
   PubMed Web of Science ®Google Scholar
• EASTELL R, HANNON RA, CUZICK J et al.: Effect of an aromatase inhibitor on bone mineral density and bone turnover markers: 2-year results of the anastrozole, tamoxifen, Alone or in Combination (ATAC) trial (18233230). J. Bone Mineral Res. (2006) 21:1215-1223.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, JOSSE RG, PRITCHARD KI et al.: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J. Clin. Oncol. (2006) 24:3629-3635.
   PubMed Web of Science ®Google Scholar
• COLEMAN RE; on behalf of the ATAC TRIALISTS’ GROUP: Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. J. Clin. Oncol. (Meeting Abstracts) (2006) 24:511.
   Google Scholar
• MCCLOSKEY E, HANNON R, LAKNER G et al.: The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: a direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women. J. Clin. Oncol. (Meeting Abstracts) (2006) 24:555.
   Google Scholar
• BUZDAR AU; on behalf of the ATAC TRIALISTS’ GROUP: Clinical features of joint symptoms observed in the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. J. Clin. Oncol. (Meeting Abstracts) (2006) 24:551.
   Google Scholar
• DUFFY S; on behalf of the ATAC TRIALISTS’ GROUP: Gynecological events including hysterctomy with anastrozole tamoxifen: Data from the ATAC (‘Arimidex’, Tamoxifen, Alone of in Combination) trial. J. Clin. Oncol. (Meeting Abstracts) (2005) 23:58s.
   Google Scholar
• HOUGHTON J; ATAC TRIALISTS’ GROUP: Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: Updated data from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. J. Clin. Oncol. (Meeting Abstracts) (2005) 23:24s.
   PubMed Web of Science ®Google Scholar
• DUFFY S, JACKSON TL, LANSDOWN M et al.: The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum. Reprod. (2006) 21:545-553.
   PubMed Web of Science ®Google Scholar
• JAKESZ R, SAMONIGG H, GREIL R et al.: Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J. Clin. Oncol. (Meeting Abstracts) (2005) 23:10s.
   Web of Science ®Google Scholar
• LAMERATO L, HAVSTAD S, GANDHI S, JONES D, NATHANSON D: Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer (2006) 106:1875-1882.
   PubMed Web of Science ®Google Scholar
• LOCKER GY; on behalf of the ATAC TRIALISTS’ GROUP: An economic evaluation of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC) from a US healthcare perspective. Proc. Am. Soc. Clin. Oncol. (2004) 23:24.
   PubMed Web of Science ®Google Scholar
• CUZICK J, SASIENI P, HOWELL A: Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br. J. Cancer (2006) 94:460-464.
   PubMed Web of Science ®Google Scholar
• PUNGLIA RS, KUNTZ KM, WINER EP, WEEKS JC, BURSTEIN HJ: Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J. Clin. Oncol. (2005) 23:5178-5187.
   PubMed Web of Science ®Google Scholar